test: update civicpy cache data (#302)

* 20240103 -> 20240325
cancervariants · Mar 26, 2024 · 1f0d61d · 1f0d61d
1 parent 6da19a6
commit 1f0d61d
Show file tree

Hide file tree

Showing 5 changed files with 5 additions and 5 deletions.
diff --git a/tests/data/harvesters/civic/civic_aid_7.json b/tests/data/harvesters/civic/civic_aid_7.json
@@ -17,8 +17,8 @@
   "evidence_ids": [
     3758,
     6178,
-    6938,
-    6940
+    6940,
+    6938
   ],
   "description": "Combination treatment of BRAF inhibitor dabrafenib and MEK inhibitor trametinib is recommended for adjuvant treatment of stage III or recurrent melanoma with BRAF V600E mutation detected by the approved THxID kit, as well as first line treatment for metastatic melanoma. The treatments are FDA approved based on studies including the Phase III COMBI-V, COMBI-D and COMBI-AD Trials. Combination therapy is now recommended above BRAF inhibitor monotherapy. Cutaneous squamous-cell carcinoma and keratoacanthoma occur at lower rates with combination therapy than with BRAF inhibitor alone.",
   "assertion_type": "PREDICTIVE",

diff --git a/tests/data/harvesters/civic/civic_molecular_profile_12.json b/tests/data/harvesters/civic/civic_molecular_profile_12.json
@@ -5,7 +5,7 @@
     12
   ],
   "name": "BRAF V600E",
-  "molecular_profile_score": 1353.5,
+  "molecular_profile_score": 1363.5,
   "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",
   "sources": [],
   "aliases": [

diff --git a/...rvesters/civic/civicpy_cache_20240103.pkl → ...rvesters/civic/civicpy_cache_20240325.pkl b/...rvesters/civic/civicpy_cache_20240103.pkl → ...rvesters/civic/civicpy_cache_20240325.pkl
diff --git a/tests/data/transform/therapeutic/civic_harvester.json b/tests/data/transform/therapeutic/civic_harvester.json
@@ -566,7 +566,7 @@
         12
       ],
       "name": "BRAF V600E",
-      "molecular_profile_score": 1353.5,
+      "molecular_profile_score": 1363.5,
       "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",
       "sources": [],
       "aliases": [

diff --git a/tests/unit/transform/test_civic_transform_therapeutic.py b/tests/unit/transform/test_civic_transform_therapeutic.py
@@ -156,7 +156,7 @@ def civic_mpid12(civic_vid12):
             },
             {
                 "name": "CIViC Molecular Profile Score",
-                "value": 1353.5,
+                "value": 1363.5,
                 "type": "Extension"
             },
             {